Regeneron Pharmaceuticals
REGN
$799.08
+0.62%
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes therapies for eye disease, cardiovascular disease, cancer, and inflammation, with key products including Eylea, Dupixent, Praluent, Libtayo, and Kevzara. As a leader in the biotech space, Regeneron is distinguished by its robust R&D engine and strategic partnerships with Sanofi and Bayer, which have driven its commercial success. The current investor narrative centers on the company's growth trajectory, particularly the performance of its core products and pipeline advancements, while also grappling with recent clinical setbacks and competitive pressures in its key therapeutic areas.…
REGN
Regeneron Pharmaceuticals
$799.08
Related headlines
Investment Opinion: Should I buy REGN Today?
Rating: Buy. Regeneron offers a compelling risk/reward with strong revenue growth, high margins, and a reasonable forward valuation. The consensus analyst target of $840.43 implies ~5.8% upside, but the high target of $1,030 suggests significant potential if pipeline successes materialize. Supporting evidence includes Q1 2026 revenue growth of 19.04% YoY, gross margin of 81.43%, operating margin of 24.95%, and a forward PE of 13.10x, which is attractive relative to the industry. The company's strong balance sheet (D/E 0.087) and free cash flow of $848.3M in Q1 support ongoing investment. Key risks include clinical trial failures and competitive pressures on Eylea. This Buy would be downgraded to Hold if revenue growth decelerates below 10% or if the forward PE exceeds 20x, and upgraded to Strong Buy if the pipeline delivers a major approval and the stock trades below $700. Overall, REGN appears fairly valued to slightly undervalued relative to its growth prospects and historical valuation range.
Sign up to view all
REGN 12-Month Price Forecast
The AI assessment leans bullish due to strong financial performance and reasonable valuation, but confidence is medium given the clinical trial risk and competitive pressures. The stock's low beta and solid fundamentals provide a defensive quality, but the recent Phase 3 failure highlights the binary nature of biotech investing. If the pipeline delivers positive data and Eylea holds up, the stock could re-rate higher. Conversely, any further setbacks could lead to a sharp decline. The stance would be upgraded to high confidence if the company reports another quarter of double-digit revenue growth and advances its pipeline, or downgraded if a major product fails.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Regeneron Pharmaceuticals's 12-month outlook, with a consensus price target around $840.43 and implied upside of +5.2% versus the current price.
Average Target
$840.43
0 analysts
Implied Upside
+5.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$730 - $1030
Analyst target range
Regeneron is covered by 27 analysts, with a consensus recommendation of 'Buy' and a mean rating of 1.89 (where 1 is Strong Buy and 5 is Sell). The average target price is $840.43, implying an upside of approximately 5.8% from the current price of $794.19. The target price range is $730.00 to $1,030.00, with the high target suggesting significant upside potential if the company's pipeline and product launches succeed. Recent analyst actions have been mixed, with some upgrades and some downgrades, reflecting uncertainty around clinical trial outcomes and competitive dynamics. The wide range of targets indicates a high degree of uncertainty about the company's future performance.
Bulls vs Bears: REGN Investment Factors
Regeneron presents a compelling investment case with strong revenue growth, high margins, and a solid balance sheet, but faces significant risks from clinical setbacks and competitive pressures. The bull case is supported by robust financials and a reasonable forward valuation, while the bear case highlights pipeline uncertainty and high PEG. Currently, the bull case has slightly stronger evidence given the company's proven commercial execution and analyst optimism, but the key tension lies in whether the pipeline can deliver new growth drivers to offset potential Eylea erosion. The outcome of upcoming clinical data and competitive dynamics will be critical in determining the stock's trajectory.
Bullish
- Strong Revenue Growth: Q1 2026 revenue grew 19.04% YoY to $3.605B, driven by Eylea and Dupixent. This robust growth outpaces the industry average and supports the company's expansion strategy.
- High Profitability Margins: Gross margin stands at 81.43% (Q1 2026), reflecting the high-margin biologics business. Operating margin is 24.95%, indicating efficient cost management and strong pricing power.
- Solid Balance Sheet: Debt-to-equity ratio is only 0.087, and current ratio is 4.13, providing ample liquidity. This financial strength supports ongoing R&D and potential shareholder returns.
- Attractive Forward Valuation: Forward PE is 13.10x, below the trailing PE of 17.92x, implying expected earnings growth. This is reasonable for a biotech leader with a robust pipeline.
Bearish
- Clinical Trial Setback: A Phase 3 trial failure for a key cancer drug combination in May 2026 caused a sharp stock drop. This highlights pipeline risk and could delay future growth catalysts.
- High PEG Ratio: PEG ratio of 3.38 suggests the stock is overvalued relative to its growth rate. This could lead to multiple compression if growth decelerates.
- Competitive Pressures: Eylea faces competition from biosimilars and newer treatments like Vabysmo. This could erode market share and pressure revenue growth in the core ophthalmology segment.
- Revenue Concentration: Heavy reliance on Eylea and Dupixent for revenue makes the company vulnerable to any setbacks in these products. Diversification is limited despite pipeline efforts.
REGN Technical Analysis
Regeneron's stock has demonstrated a strong recovery over the past year, with a 1-year price change of +37.02%, and is currently trading at $794.19, which is approximately 93.8% of its 52-week range (low of $541.00, high of $847.00). This positioning near the upper end of the range suggests robust momentum and investor confidence, though it also raises the possibility of overextension. The stock's beta of 0.188 indicates significantly lower volatility compared to the broader market, which may appeal to risk-averse investors but also implies less dramatic upside potential.
Beta
0.19
0.19x market volatility
Max Drawdown
-26.1%
Largest decline past year
52-Week Range
$541-$847
Price range past year
Annual Return
+37.6%
Cumulative gain past year
| Period | REGN Return | S&P 500 |
|---|---|---|
| 1m | +4.8% | +2.7% |
| 3m | +32.5% | +1.0% |
| 6m | +1.5% | +12.0% |
| 1y | +37.6% | +18.9% |
| ytd | +2.9% | +12.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
REGN Fundamental Analysis
Regeneron's revenue has been growing steadily, with the most recent quarter (Q1 2026) reporting revenue of $3.605 billion, a 19.04% year-over-year increase. This growth is driven by strong product sales, particularly Eylea and Dupixent, as well as collaboration revenue. The company's profitability is robust, with a net income of $727.2 million in Q1 2026 and a gross margin of 81.43%, reflecting its high-margin biologics business. Regeneron's balance sheet is solid, with a debt-to-equity ratio of 0.087 and a current ratio of 4.13, indicating strong liquidity and financial flexibility. The company generated $1.079 billion in operating cash flow in Q1 2026, and its free cash flow of $848.3 million supports ongoing investment in R&D and shareholder returns.
Quarterly Revenue
$3.6B
2026-03
Revenue YoY Growth
+19.0%
YoY Comparison
Gross Margin
81.4%
Latest Quarter
Free Cash Flow
$4.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is REGN Overvalued?
Given Regeneron's positive net income, the price-to-earnings (PE) ratio is the most appropriate valuation metric. The trailing PE is 17.92x, while the forward PE is 13.10x, indicating that the market expects significant earnings growth. This is supported by a PEG ratio of 3.38, which suggests the stock may be overvalued relative to its growth rate. Compared to the industry average, Regeneron's PE is at a premium, reflecting its strong market position and growth prospects. Historically, the stock's PE has ranged from as low as 4.73x in 2021 to over 36x in early 2024, and the current level is near the lower end of this range, suggesting potential value.
PE
17.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 5x~28x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include moderate debt (D/E 0.087) and high R&D spending ($1.645B in Q1 2026), which could pressure margins if revenue growth slows. However, strong operating cash flow ($1.079B in Q1) and a current ratio of 4.13 provide a cushion. The company's profitability is solid, but any significant decline in Eylea sales due to biosimilar competition could impact earnings. Market risks include valuation compression if the stock's premium PE (17.92x trailing) contracts, especially given the PEG of 3.38. The stock's beta of 0.188 suggests low market correlation, but it is still sensitive to biotech sector sentiment and regulatory news. Recent clinical trial failure highlights the inherent risk of drug development, which could lead to further downgrades. In a worst-case scenario, if Eylea faces rapid biosimilar erosion and the pipeline fails to deliver, the stock could drop to its 52-week low of $541, representing a -31.9% decline from the current price of $794.19. This would be compounded by potential analyst downgrades and a loss of investor confidence, leading to a prolonged period of underperformance.